MRK

Merck & Co
D

MRK

Arincen67/100B

Merck & Co cash flow statement 1989–2026

Merck & Co's free cash flow over the last twelve months was 14.75B USD: operating cash flow of 18.70B USD less 3.96B USD of capital spending. That is 21.9% of its revenue and 5.95 a share.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Net income
2.45B18.25B17.13B365.00M14.53B12.36B7.08B9.78B6.19B2.42B3.94B
Depreciation and amortization
7.34B5.84B4.50B3.87B3.91B3.21B3.49B3.65B4.52B4.68B5.47B
Stock-based compensation
1.06B0.00761.00M645.00M541.00M479.00M441.00M417.00M348.00M312.00M300.00M
Change in working capital
-2.50B-6.98B-3.67B-2.21B-2.78B-3.84B-4.59B-2.07B-1.55B-5.02B-2.60B
Change in receivables
—-1.09B-244.00M-1.15B-644.00M-2.03B-1.00B294.00M-418.00M297.00M-619.00M
Change in inventory
—-1.18B-835.00M-816.00M-161.00M-674.00M-855.00M-508.00M-911.00M-145.00M206.00M
Change in payables
—110.00M182.00M-380.00M-289.00M405.00M724.00M399.00M230.00M254.00M278.00M
Change in other working capital
-225.00M-4.82B-2.77B139.00M-1.69B-1.54B-3.46B-2.25B-454.00M-5.43B-2.47B
Other non-cash items
11.82B1.03B3.99B12.23B4.47B1.71B4.50B2.22B1.92B6.68B4.79B
Operating cash flow
18.70B16.47B21.47B13.01B19.10B14.11B10.25B13.44B10.92B6.45B10.38B
Operating cash flow growth
+9.60%-23.27%+65.06%-31.89%+35.34%+37.61%-23.71%+23.05%+69.41%-37.87%-16.46%
Capital expenditure
-3.96B-4.11B-3.37B-3.86B-4.39B-4.45B-4.43B-3.47B-2.62B-1.89B-1.61B
Acquisitions
—-10.04B-4.09B-12.03B-121.00M-12.91B-6.61B-4.95B-431.00M-396.00M-780.00M
Purchases of investments
—-1.21B-519.00M-955.00M-1.20B-1.00M-1.10B-3.20B-7.99B-10.74B-15.65B
Sales and maturities of investments
—1.68B377.00M1.66B721.00M1.03B2.81B8.62B15.25B15.66B14.35B
Other investing
-5.75B-58.00M-127.00M1.11B32.00M-225.00M130.00M378.00M102.00M38.00M482.00M
Investing cash flow
-28.33B-13.74B-7.73B-14.08B-4.96B-16.56B-9.44B-2.63B4.31B2.68B-3.21B
Debt issued (repaid)
—11.38B2.31B4.18B-2.25B1.63B5.01B1.25B837.00M-1.13B-1.31B
Shares issued
494.00M92.00M0.000.00384.00M0.000.000.000.000.000.00
Share buybacks
-3.54B-5.08B-1.31B-1.35B0.00-840.00M-1.28B-4.78B-9.09B-4.01B-3.43B
Dividends paid
-8.37B-8.18B-7.84B-7.45B-7.01B-6.61B-6.22B-5.70B-5.17B-5.17B-5.12B
Other financing
-156.00M-131.00M-195.00M-203.00M-240.00M8.41B-347.00M366.00M266.00M304.00M821.00M
Financing cash flow
1.10B-1.92B-7.03B-4.81B-9.12B2.59B-2.83B-8.86B-13.16B-10.01B-9.04B
Net change in cash
-8.55B1.37B6.41B-5.86B4.61B14.00M-1.77B1.97B1.87B-423.00M-2.01B
Free cash flow
14.75B12.36B18.10B9.14B14.71B9.66B5.82B9.97B8.31B4.56B8.76B
Free cash flow growth
+13.00%-31.70%+97.92%-37.83%+52.23%+65.88%-41.57%+19.98%+82.21%-47.97%-21.33%
Free cash flow margin
21.91%19.04%28.20%15.21%24.81%19.84%14.03%25.48%19.64%11.36%22.01%
Free cash flow per share
5.954.937.123.595.793.812.293.863.101.663.14
Free cash flow per share growth
+14.98%-30.77%+98.39%-37.95%+51.99%+66.08%-40.67%+24.59%+86.90%-47.23%-19.81%
Income taxes paid
—0.000.000.000.000.000.000.000.000.000.00

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Merck & Co's cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.